Shareholder pressures Capricor; Lilly dives deeper into vaccines

Summary

Kaos Capital is pressuring Capricor for governance changes to alter the Duchenne cell therapy maker's strategic direction. Bristol Myers Squibb is expanding its AI-powered drug discovery capabilities while Eli Lilly deepens vaccine development efforts.